Vivalink Releases Biometrics Data Platform 2.0, Increasing Remote Patient Monitoring Patient Adherence

New updates address common industry challenges for RPM patient adherence in clinical trials and healthcare

Vivalink, a leading provider of digital healthcare solutions, has released an updated version of its Biometrics Data Platform with new features aimed at increasing patient adherence in Remote Patient Monitoring (RPM).

Vivalink’s Biometrics Data Platform accelerates the implementation and time-to-market of remote patient monitoring for healthcare and clinical trials by combining a turn-key end-to-end solution consisting of a suite of wearable sensors, edge-to-cloud integration, and advanced data  management and analytics both in real-time and retrospectively. The software platform is designed for flexible interoperability with mobile and web enabled clinical applications, electronic health record (EHR) systems and clinical trial management systems (CTMS).

While the adoption of RPM has accelerated with the pandemic and is expected to grow exponentially, patient adherence remains a top challenge. In a Decentralized Clinical Trial (DCT) survey by Vivalink, 69 percent of respondents indicated ‘patient adherence’ as the top concern.

To address this concern, the new Biometrics Data Platform updates include:

  • Data Integrity Assurance – notification of interruptions in data capture
  • New Adhesives Options – designed for sensitive skin and facilitates extended wear times
  • Sensor Status Indicators – detects when sensors are not connected or have become disconnected
  • Central Operational Console – systems management view of distributed patient sensors and data capture status across multiple locations to ensure proper adherence
  • Data Management Portal – A multi-functional web portal for patient/participant management, vital data visualization, analysis, and notifications based on advanced algorithms

Vivalink takes a “patient centric” approach to its RPM solution, which includes making its devices as easy to use and comfortable as possible for the patient. For example, its medical grade multi-vital cardiac patch is among the world’s smallest and lightest, weighing just 7.5 grams, increasing comfort while reducing disruption to daily routines.

“As a technology solution provider, we strive for the most advanced and effective solutions for remote patient monitoring,” said Jiang Li, CEO of Vivalink. “Patient adherence is a major bottleneck for the wider adoption of RPM. Today’s release of these features focusing on improving patient adherence shows our firm commitment to the patient-centric approach of our solution.

”More than 150 digital healthcare solution partners and commercial customers in 41 countries are delivering a wide range of medical applications using Vivalink’s Biometrics Data Platform. Vivalink’s solution is the basis of clinical research studies at leading institutions, including a 3,000 patient atrial fibrillation study at UCSF and a study of the effects of stress and teenage depression at Stanford University. Most recently, the platform has been adopted by health technology companies developing AI solutions, algorithm development and validation. The platform meets high levels of global compliance, including HIPAA, GDPR, FDA 21 CFR Part 11, ISO 13485, IEC 62304, ISO 14971, ISO 10993, and ISO 27001.

For more information, visit www.vivalink.com.

SourceVivalink

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.